Summary: The aim of this study was to examine in vitro, by means of kinetic analysis and molecular docking simulations, the effects of the flavone diosmetin and its flavanone analog hesperetin on CYP (cytochrome P450) 2C9-mediated drug metabolism. To this purpose, the conversion of diclofenac to 4?-hydroxydiclofenac by human liver microsomes was used as a model assay for assessing the CYP2C9 inhibitory activity of these two flavonoids. Kinetic analyses showed that diosmetin and hesperetin were reversible, dead-end inhibitors of 4?-hydroxydiclofenac formation; their mean K i (inhibitor dissociation constant) values were 1.71± 0.58 and 21.50±3.62 mM, respectively. Diosmetin behaved as a competitive inhibitor, since it increased markedly the Km (substrate concentration yielding 50z of Vmax) of the reaction without affecting the Vmax (maximum velocity of reaction). Hesperetin modified markedly Km and to a lesser extent also modified Vmax, thus acting as a mixed competitive-noncompetitive inhibitor. The results of molecular docking simulations were consistent with those of kinetic analysis, since they showed that the putative binding sites of both diosmetin and hesperetin coincided with the CYP2C9 substrate binding site.
Flavonoids are naturally occurring polyphenolic secondary plant metabolites widely distributed in foods of plant origin and, therefore, ingested with the diet by human beings, depending on habits and customs. 1) Flavonoids have been associated with a variety of beneficial effects mediated by a plethora of different mechanisms. 2, 3) By virtue of their antioxidant activity, 4) they are presumed to protect tissues against oxidative stress and associated pathologies such as coronary artery disease and inflammation. 5) Their ability to inhibit the formation of carcinogenic products is considered responsible for their cancer-preventive properties. 6) For these reasons, the use of dietary supplements and herbal preparations containing flavonoids has become very popular in recent years and is constantly increasing, in spite of their potential for interaction with co-administered drugs. 7) Moreover, in various countries, flavonoids are currently used as therapeutic agents. For example, diosmin (the 7-rhamnoglucoside of 3?,5,7-trihydroxy-4?-methoxyflavone) and hesperidin (the 7-ramnoglucoside of 3?,5,7-trihydroxy-4?-methoxyflavanone) ( Fig. 1) , besides being natural constituents of foods of plant origin, Fig. 1 . Structures of the natural flavonoids diosmin and hesperidin, and their respective aglycones diosmetin (3?,5,7-trihydroxy-4?-methoxyflavone) and hesperetin (3?,5,7-trihydroxy-4?-methoxyflavanone) The S-configuration is shown for hesperidin/hesperetin, since the naturally occurring flavonoid is almost exclusively present as the 2S epimer. 54) by intestinal mucosa and liver, and their bioavailability is consequently low, with peak values of plasma concentrations in the low micromolar range, 7, 12, 13) recent clinical studies demonstrated that certain flavonoids modify the pharmacokinetics of some co-administered drugs. [14] [15] [16] [17] [18] In particular, Rajnarayana et al. 17) reported that pretreatment of healthy volunteers with diosmin (500 mg once daily for 9 days) significantly impairs the oral disposition kinetics of DCF (diclofenac), a non-steroidal anti-inflammatory drug oxidized almost exclusively by cytochrome P450 (CYP) 2C9, since the area under the curve (AUC) and half-life (t1/2) of DCF are significantly increased, and oral clearance (CL/F) is decreased. 17) As a possible explanation for the alteration of DCF disposition kinetics, these authors proposed that diosmin inhibits CYP2C9, the enzyme mainly responsible for DCF biotransformation.
To the best of our knowledge, no in vitro data are available in the literature showing that CYP2C9-mediated drug metabolism is inhibited by diosmin or its absorbable aglycone diosmetin, 19) to which it is converted by the rhamnosidases of enterobacteria. 20) In a recent work, Si and coworkers 21) investigated the mechanism of inhibition of CYP2C9-mediated DCF metabolism by a series of 11 different flavones which, however, did not include diosmetin. Therefore, the main aim of the present study was to investigate in vitro the possible inhibitory effect of diosmetin on the drug metabolizing activity of human CYP2C9 by assessing the conversion of DCF to 4?-OH-DCF (4?-hydroxydiclofenac), a validated marker reaction of CYP2C9. 22) An additional aim of our study was to ascertain whether hesperetin (the flavanone analogue of diosmetin) can also affect CYP2C9-mediated drug metabolism. Two considerations prompted us to assess the effect of hesperetin. First, as mentioned above, hesperidin is present together with diosmin in a widelyused pharmaceutical preparation (Daflon500) and is also likely to be hydrolyzed by intestinal microflora to its aglycone hesperetin. 20, 23) Second, Spanakis et al. 24) have recently demonstrated that diosmetin is partly converted in vivo to hesperetin through reduction of the double-bond of its C-ring (Fig. 1) by the bacteria of the intestinal microflora. Accordingly, we evaluated the effects of both diosmetin and hesperetin on CYP2C9-mediated DCF metabolism by HLMs (human liver microsomes) and characterized their mechanisms of inhibition by means of both enzyme kinetic studies and molecular docking simulations, since these two techniques provide useful complementary information regarding the mechanisms of drug-enzyme interactions.
Materials and Methods
Reagents: Diosmetin and hesperetin were purchased from Chromadex (Irvine, CA, USA). DCF sodium salt and 4?-OH-DCF were from Merck Biosciences (Darmstadt, Germany). N,N-dimethylformamide (DMF), 4-nitrobenzoic acid (HPLC grade) and NADPH were purchased from Sigma-Aldrich Italy (Milan, Italy). Methanol and acetonitrile (both of HPLC grade) were from Carlo Erba Reagenti (Milan, Italy). Ultrapure water was obtained by means of a Pure-Lab Option Q (Elga Lab-Water, High Wycombe, UK) apparatus.
Diosmetin and hesperetin were dissolved in DMF, which is reportedly the solvent with the lowest inhibitory activity against CYP2C9. 25) Solutions of the flavonoids were prepared daily and kept in ice until use. The final solvent concentration in the incubation medium was 0.5%.
HLMs and human cDNA-expressed CYP2C9 microsomal preparations: Pooled mixed-gender HLMs (obtained from 25 female and 27 male donors) were provided by Xenotech LLC (Lenexa, KS, USA).
Recombinant CYP2C9 (rCYP2C9), co-expressed with human NADPH-cytochrome P450-reductase and cytochrome b5 in insect cell microsomes (Supersomes), was purchased from BD Gentest (Woburn, MA, USA). The expression level of CYP2C9, NADPH-cytochrome P450-reductase, and cytochrome b5, as well as their specific activities, were provided in the manufacturer's data sheets. All microsomal fractions were stored in aliquots at -809 C until use.
Determination of 4?-OH-DCF formation rate by HLMs:

Incubation conditions
Incubation of DCF with HLMs was carried out in conditions yielding a linear reaction rate with respect to incubation time and microsomal protein concentration. HLMs (final protein concentration 0.05 mg/ml) were incubated in a mixture (total volume: 600 ml) containing 50 mM KH2PO4 (pH 7.4), 0.5 mM NADPH, and increasing concentrations of DCF (1-50 mM). In some experiments, the incubation medium contained 0.5% (final concentration) of the flavonoid solvent DMF. After a 3-min thermal equilibration at 379 C of the incubation mixtures, the reaction was started by the addition of 0.5 mM NADPH and was allowed to proceed for 20 min in a shaking water bath at 379 C in aerobic conditions before being stopped by addition of 60 ml of ice-cold methanol containing 5 mM 4?-nitrobenzoic acid as internal standard. After denatured proteins were removed by centrifugation for 10 min at 20000 g, aliquots (550 ml) of the supernatants were transferred to 1.5-ml Eppendorf tubes, frozen under liquid nitrogen and lyophilized. The residues were reconstituted with 150 ml of ultra-pure water and analyzed by high performance liquid chromatography (HPLC) with UV detection, as described below.
To determine the effects of diosmetin and hesperetin on 4?-OH-DCF production, HLMs (final protein concentration 0.05 mg/ml) were incubated in the absence or presence of increasing concentrations of diosmetin (from 0.5 to 25 mM, n＝8) or hesperetin (from 1 to 100 mM, n ＝7) in the above-specified incubation mixture containing 5 mM DCF. Control samples contained 0.5% DMF. Incubations were carried out as specified above and were stopped after 20 min of incubation at 379 C by addition of 60 ml of ice-cold methanol containing 5 mM 4?-nitrobenzoic acid. The samples were then processed as described above.
In order to characterize the kinetic mechanism of inhibition of DCF metabolism by diosmetin and hesperetin, 4?-OH-DCF formation catalyzed by HLMs (final protein concentration 0.05 mg/ml) was determined in the abovespecified incubation mixture containing increasing concentrations of DCF (ranging from 1 to 40 mM, n＝6) in the absence or presence of three concentrations of diosmetin (1, 2.5, 4 mM) or hesperetin (5, 15, 25 mM).
HPLC analysis
Quantitative evaluation of 4?-OH-DCF formation was carried out using a Hewlett-Packard series 1100 HPLC system equipped with degasser, quaternary pump, autosampler, and multiple-wavelength detector (Agilent, formerly Hewlett-Packard GMBH, Germany); chromatographic data were collected and integrated by means of the Hewlett-Packard ChemStation software (version A.06.03). Chromatographic conditions were: column, Zorbax Eclipse XDB-C8 (4.6×150 mm, 5 mm, Agilent Technologies Inc., Palo Alto, CA, USA); mobile phase, 20 mM KH2PO4 (pH 7.4)/acetonitrile (84:16 v/v, solvent A) and acetonitrile (solvent B); elution program, isocratic elution with 100% solvent A for 5 min, followed by 20-min linear gradient elution from 0 to 45% solvent B; flow rate, 1.2 ml/min; injection volume, 100 ml; column temperature, 269 C; detection, UV absorbance at 282 nm. In the above conditions, retention times of DCF and 4?-OH-DCF were 14.7 and 11.6 min, respectively. Quantitative determination of 4?-OH-DCF was carried out by means of standard calibration curves obtained with increasing concentrations of authentic 4?-OH-DCF (from 0.08 to 2 nmol/0.6 ml, n＝7) processed exactly as the samples were. The calibration curves were linear in this concentration range (r 2 AE0.99), the lowest value of the range representing the limit of quantification of the assay. The inter-and intra-assay coefficients of variation (CV) for 4?-OH-DCF determination (n＝5) at 0.08 and 2 nmol/0.6 ml were less than 5%.
Data analysis
Initial velocity (v) data for 4?-OH-DCF formation catalyzed by HLMs were evaluated by graphical analysis with the Eadie-Hofstee plot (v vs v/[S]), the plotting technique most sensitive to deviations from linearity, 26) and by bestfitting procedures by means of GraphPad Prism software, version 5.03 (GraphPad Software Inc., San Diego, CA, USA). The F test was used to discriminate between different kinetic models (i.e., one-or two-site hyperbolic Michaelis-Menten model, or Michaelis-Menten kinetics with substrate inhibition). Kinetic parameters, estimated by non-linear regression analysis of untransformed data (GraphPad Prism software), were: Vmax, Km and CLint (intrinsic metabolic clearance), calculated as Vmax/Km.
The maximal inhibition (imax) by diosmetin and hesperetin of DCF conversion to 4?-OH-DCF was evaluated by means of the graphical method described by Palatini. 27) In this plot, if the experimental concentrations of the inhibitor are marked on a negative horizontal axis and the corresponding fractional inhibition (i) values are marked on a vertical axis, the straight lines drawn through each pair of points intersect at a common point whose ordinal coordinate represents the imax value.
The kinetic mechanisms of the flavonoid-induced inhibition of 4?-OH-DCF production were inferred from their effects on Vmax and Km, obtained as specified above, using the one-site Michaelis-Menten model. For this analysis, diosmetin and hesperetin were considered dead-end inhibitors (see Results and Discussion). Lineweaver-Burk (double-reciprocal) plots were used for graphical presentation of the inhibitory effects of diosmetin and hesperetin on 4?-OH-DCF formation. Since preliminary dilution experiments showed that both flavonoids caused reversible inhibition of CYP2C9 activity (results not shown), we calculated the dissociation constant of the inhibitor-en-zyme complex (Ki). To this purpose, the kinetic data were fitted to a competitive (diosmetin) or mixed inhibition model (hesperetin) by nonlinear regression analysis (GraphPad Prism, version 5.03) using the appropriate equations. 28) Statistical analyses were performed with GraphPad Prism 5.03 software. All values are expressed as arithmetic means±S.E.M. Comparison of experimental data obtained in the presence of increasing concentrations of the inhibitor with data obtained in the absence of the inhibitor (control values) was made by one-way analysis of variance (ANOVA) followed by Dunnett's post-hoc test. Pº0.05 was considered statistically significant. Evaluation of the metabolic stability of diosmetin and hesperetin in the presence of rCYP2C9
Diosmetin (final concentration 25 mM) or hesperetin (final concentration 100 mM) was incubated for 20 min at 379 C in a medium (final volume: 200 ml) consisting of 0.1 M KH2PO4 (pH 7.4) in the absence or presence of 10 pmol/ml rCYP2C9 plus 0.5 mM NADPH. The reactions were started by the addition of the flavonoid and stopped by means of 50 ml ice-cold acetonitrile. Denatured proteins were removed by centrifugation for 10 min at 20000 g, and aliquots (100 ml) of the supernatants were analyzed by HPLC with UV detection. The analysis was carried out using the Hewlett-Packard series 1100 HPLC system described above (see HPLC analysis).
Chromatographic conditions were: column, Eclipse XDB-C8 (4.6×150 mm, 5 mm, Agilent Technologies Inc., Palo Alto, CA, USA) with a pre-column Agilent Eclipse XDB C8 (5 mm; 4.6×12.5 mm); mobile phase, 20 mM ammonium acetate (pH 4.5)/methanol (70:30 v/v, solvent A) and acetonitrile (solvent B); elution program, isocratic elution with 100% solvent A for 5 min, followed by 15-min linear gradient elution from 0 to 15% solvent B, and then isocratic elution with 15% solvent B for a further 11 min. Flow rate, 1.2 ml/min; injection volume, 90 ml; column temperature, 309 C; detection, UV absorbance at 254 nm. Under the above conditions, retention times of authentic diosmetin and hesperetin were 22.5 and 21 min, respectively.
Molecular docking simulations: Target structures
Human CYP2C9 complexed with flurbiprofen was retrieved from the Protein Data Bank (PDB code: 1R9O) 29) and processed in order to remove the ligands and water molecules. Hydrogen atoms were added to the protein structure using standard geometries with the Molecular Operation Environment (MOE, version 2008.10) program. 30) To minimize contact between hydrogen atoms, the structures were subjected to Amber94 31) force field minimization until the rms of the conjugate gradient was º0.1 kcal/mol/°A, keeping the heavy atoms fixed at their crystallographic positions.
Molecular docking protocol
All docked ligands were built using the Builder module of MOE. 30) Ligands were docked into the putative heme binding sites using the flexible MOE-Dock methodology. 30) The purpose of MOE-Dock is to search for favorable binding configurations between a small, flexible ligand and a rigid macromolecular target. Searching is conducted within a user-specified 3D docking box, using the tabu search protocol 32) and MMFF94 force field. 33) Charges for ligands were imported from the MOPAC (Molecular Orbital PACkage) program 34) output files. MOE-Dock performs a user-specified number of independent docking runs (55 in the presented case) and writes the resulting conformations and their energies to a molecular database file. The resulting ligand-CYP2C9 complexes were subjected to MMFF94 all-atom energy minimization until the rms of the conjugate gradient was º0.1 kcal/mol/°A. The GB/SA (Generalized Born and Surface Areas) approximation 35) was used to model the electrostatic contribution to the free energy of solvation in a continuum solvent model. The interaction energy values were calculated as the energy of the complex, minus the energy of the ligand, minus the energy of CYP2C9: DEinter＝E(complex)-(E(L)＋E(CYP2C9)).
Results
Conversion of DCF to 4?-OH-DCF by HLMs:
We preliminarily evaluated DCF conversion to 4?-OH-DCF by HLMs over a substrate concentration range of 1-50 mM in the absence and presence of DMF (final concentration: 0.5%), which was used in this study to solubilize diosmetin and hesperetin, since it had been shown to be the solvent with the least inhibitory activity against CYP2C9. 25) Consistent with the results of graphical analysis, which yielded linear Eadie-Hofstee plots, (insets of Fig. 2) , untransformed initial velocity data for 4?-OH-DCF formation by HLMs were best fitted by the one-site Michaelis-Menten model, both in the absence and presence of DMF (Fig. 2) . These analyses indicated that a single enzyme following classical Michaelis-Menten kinetics 26) was involved in the 4?-hydroxylation of DCF in the above-specified concentration range. The addition of 0.5% DMF had no significant effect (PÀ0.05) on the values of the kinetic parameters of this enzymatic reaction: Vmax was 3.04±0.27 and 2.91±0.19 nmol/min/mg protein in the absence and presence of the solvent, respectively; Km was 10.07±0.08 and 9.76±0.40 mM, respectively, and CLint (0.301±0.02 ml/min/mg protein) remained virtually unchanged.
Effects of diosmetin and hesperetin on DCF 4?-hydroxylation by HLMs: The effects of the two flavonoids on DCF metabolism were tested at a substrate concentration (5 mM) close to the Km value of the reaction. Figure 3 shows that both diosmetin and hesperetin decreased 4?-OH-DCF formation in a concentration- dependent manner and that diosmetin was more potent than hesperetin as an inhibitor of the 4?-hydroxylation reaction, mean IC50 values being 3.55±0.27 and 25.73 ±1.74 mM, respectively. The effects of diosmetin and hesperetin at concentrations exceeding 25 and 100 mM, respectively, were not reported because the amount of 4?-OH-DCF recovered in the incubation mixture fell under the quantification limit. Since diosmetin has previously been shown to be a partial inhibitor of CYP3A4/5, 36) to ascertain unequivocally whether diosmetin and hesperetin are partial or full inhibitors of DCF metabolism by HLMs, we analyzed the results by means of the plot described by Palatini, 27) which allows a straightforward determination of maximal fractional inhibition values even when saturating inhibitor concentrations cannot be tested. Figure 4 clearly shows that both diosmetin and hesperetin behaved as full inhibitors of 4?-OH-DCF formation by HLMs since, for both flavonoids, the lines intersect at a common point whose ordinal coordinate (representing imax) is equal to 1.
Mechanism of inhibition by diosmetin and hesperetin of 4?-OH-DCF formation: In order to determine the type of inhibition caused by the flavonoids on 4?-OH-DCF formation, the kinetics of 4?-OH-DCF production were evaluated in the absence and presence of three concentrations of diosmetin (1, 2.5, 4 mM) and hesperetin (5, 15, 25 mM). The data are shown in Figure  5 as Lineweaver-Burk (double-reciprocal) plots. These plots indicate that diosmetin behaved as a competitive inhibitor of 4?-OH-DCF formation by HLMs, whereas hesperetin inhibited the reaction in a mixed competitivenon competitive manner. Untransformed initial velocity data were best fitted by the one-site Michaelis-Menten model also in the presence of diosmetin or hesperetin, indicating that the two flavonoids did not modify the kinetic pattern of the diclofenac 4?-hydroxylation reaction (data not shown). The results of non-linear regression analysis confirmed the indications of the graphical analyses, since they indicate that diosmetin increased Km in a concentration-dependent manner, without significantly affecting Vmax. (Table 1) . Moreover, diosmetin significantly reduced CLint in a concentration-dependent manner. The results reported in Table 2 confirm that The Ki values of the two flavonoids, which are an inverse measure of their affinity for the enzyme, were obtained by nonlinear regression analysis (see Methods).
Mean Ki values (from 3 experiments in duplicate) were 1.71±0.58 and 21.50±3.62 mM for diosmetin and hesperetin, respectively. Similar Ki values (1.86±0.24 and 23.14±3.10 mM for diosmetin and hesperetin, respectively) were obtained by using the method of Segel, 26) i.e., by replotting the slope of each double reciprocal plot vs. the corresponding inhibitor concentration (data not shown).
Molecular docking simulation: The structure of human CYP2C9 complexed with flurbiprofen (1R9O structure) has been determined at 2.0-°A resolution by x-ray crystallography. 29) Yan et al. 37) have subsequently published a CYP2C9-DCF complex structure assuming that DCF binds to human CYP2C9 and rabbit CYP2C5 in a very similar bonding mode. We examined the competition between DCF and flurbiprofen for binding to the active site of the 1R9O structure and performed computer-based automated docking of DCF using the MOE-Dock program described above (see Materials and Methods). Figure 6 depicts the binding mode of DCF in the CYP2C9 heme active site. Similarly to what had previously been observed for the CYP2C9-flurbiprofen complex, 29) the phenyl acetic acid ring of DCF was located distal to the heme group, and the site of hydroxylation (at the 4?-position) was 4.9°A from the heme iron, a distance similar to those observed with other CYP-substrate complexes. 29, 37) Like flurbiprofen, DCF packed next to helix I in a hydrophobic cleft delimited by Val113, Phe114, Ile205, Leu208 and Phe476. This cleft surrounded DCF on three sides but left the carboxylate moiety exposed to the solvent in the large active site cavity. Moreover, the 1R9O structure revealed that Arg108 plays a significant role in the binding of DCF and flurbiprofen to the enzyme.
To explore the possibility that diosmetin and hesperetin compete with DCF for the same binding site on CYP2C9, molecular modeling studies have been carried out using the MOE-Dock program. Docking simulations (Fig. 7) showed that diosmetin and hesperetin accommodated in the same hydrophobic cleft as DCF, both adopting energetically stable conformations. They were oriented with the hydroxyl-methoxy-phenyl moieties (B ring in Fig. 1 ) close to the heme group, and the 7-OH group of chromone or dihydro-chromone moieties of diosmetin and hesperetin, respectively (A and C rings in Fig. 1 ), exposed to the solvent in the large active site cavity, as above described for the carboxylate groups of DCF and flurbiprofen. The values of the interaction energies for diosmetin-and hesperetin-CYP2C9 complexes were about 15-20 kcal/mol lower than the DCF interaction energy. No stabilizing ionic interaction with Arg108 was observed with either flavonoid, which may provide a plausible explanation for the reduced stability of the diosmetin-and hesperetin-CYP2C9 complexes with respect to the DCF-enzyme complex. Moreover, the diosmetin-CYP2C9 complex proved to be about 5 kcal/mol more stable than the hesperetin-CYP2C9 complex.
Evaluation of the stability of diosmetin and hesperetin to metabolism by rCYP2C9: Based on the results obtained from molecular docking studies indicating that diosmetin and hesperetin bind to the same site as that occupied by DCF, we considered the possibility that both flavonoids may also behave as substrates of CYP2C9. Therefore, experiments were performed in order to evaluate the stability of the two flavonoids to CYP2C9-mediated metabolism by using NADPH-supplemented human rCYP2C9. As shown in Figure 8 , the HPLC profiles obtained upon incubation of diosmetin or hesperetin with rCYP2C9 plus NADPH were identical to those of control samples incubated in the absence of rCYP2C9. Moreover, the chromatographic peak areas of diosmetin and hesperetin were virtually identical in the presence and absence of rCYP2C9, indicating that neither flavonoid was a substrate of CYP2C9.
Discussion
Various clinical studies have shown that therapeutic doses of flavonoids can interfere with the disposition kinetics of several drugs. [14] [15] [16] 18) On the basis of in vivo or in vitro evidence, inhibition of the CYP forms responsible for the metabolism of co-administered drugs has been proposed as the mechanism responsible for the pharmacokinetic interactions caused by flavonoids. No study has yet tried to identify the mechanism underlying the interference of diosmin with the oral disposition kinetics of DCF, 17) a non-steroidal anti-inflammatory agent mainly metabolized by CYP2C9. The present study has addressed the question of the possible inhibitory effects of diosmetin and hesperetin, the absorbable aglycones of diosmin and hesperidin, respectively, 19, 20) on CYP2C9-mediated drug metabolism. To assess the effects of diosmetin and hesperetin on CYP2C9-catalyzed drug metabolism, we measured the 4?-hydroxylation of DCF, since this reaction is a validated marker of CYP2C9 activity in HLMs. 22) Besides explaining the effect of diosmin on the oral disposition kinetics of DCF, 17) our demonstration that diosmetin and hesperetin are potent inhibitors of CYP2C9 is of general clinical relevance, since this CYP form is one of the most important human CYPs, metabolizing approximately 20% of currently marketed drugs, 38) some of which (e.g., warfarin, phenytoin, tolbutamide) have a narrow therapeutic index. 39) Our kinetic experiments, performed under rigorously controlled initial-rate conditions, yielded linear EadieHofstee plots for the conversion of DCF to 4?-OH-DCF, and the untransformed initial velocity data were best fitted by the one-site Michaelis-Menten kinetic model, indicating the involvement of a single enzyme in DCF biotransformation. 26) The values of kinetic parameters, obtained by the best fitting procedure, are very similar to those recently reported for HLMs by Tang et al.
40)
The substrate inhibition of DCF 4?-hydroxylation observed by these authors is due to their use of much higher DCF concentrations (up to 250 mM) than those employed for our kinetic experiments. Substrate inhibition was not found by the same authors when 4?-OH-DCF formation by HLMs was measured at DCF concentrations up to 25 mM 41) or by other authors using DCF concentrations up to 100 mM. 42, 43) A further observation of methodological interest is that DMF, the solvent used to dissolve diosmetin and hesperetin, has no effect on the kinetic parameters of DCF 4?-hydroxylation by HLMs when used at a final concentration of 0.5%. This result confirms the suggestion of Hickman et al. 25) that DMF is the preferred organic solvent when non-hydrophilic compounds are to be added to the incubation medium for assay of CYP2C9 activity.
The main findings regarding the inhibition of CYP2C9 drug metabolizing activity by the flavone diosmetin and its analogue flavanone hesperetin can be summarized as follows:
1) Both flavonoids inhibit in a concentration-dependent manner the CYP2C9-mediated 4?-hydroxylation of DCF by HLMs, diosmetin being about 12-fold more potent than hesperetin on the basis of Ki values (1.7 and 21.5 mM for diosmetin and hesperetin, respectively). The computed interaction binding energies obtained by molecular docking simulations are consistent with the relative Ki values, since they also indicate that diosmetin has a higher affinity than hesperetin for the enzymatic protein. This is probably explained by the lack of planarity of the dihydro-chromone moiety in the hesperetin molecule (see Fig. 7 ), which may increase steric hindrance during binding recognition.
From the Ki values determined in this study, the inhibitory potencies of diosmetin and hesperetin appear of the same order of magnitude as those previously reported for the flavonoids baicalein and 6-hydroxyflavone, for which Ki values of 4 and 11 mM, respectively, have been reported. 21) Moreover, diosmetin (IC50 value of 3.5 mM) appears to be as potent as another known CYP2C9 inhibitor, avasimibe, for which an IC50 value of 2.9 mM has been obtained. 44) 2) At variance with previous observations indicating that diosmetin is a partial inhibitor of CYP3A4/5-mediated midazolam metabolism (maximal inhibition 89%), 36) both flavonoids proved to be full inhibitors of CYP2C9 activity.
3) According to kinetic analyses, diosmetin behaves as a competitive inhibitor of DCF metabolism, an observation consistent with the results of molecular docking simulations indicating identical binding sites for diosmetin and DCF. Unlike diosmetin, hesperetin was found to behave as a mixed competitive-non competitive inhibitor of 4?-OH-DCF formation on the basis of kinetic evidence. The results of molecular docking simulations cannot explain the non-competitive component of hesperetin's inhibition of DCF metabolism, since they indicate virtually identical binding sites for the two flavonoids. However, by showing that both diosmetin and hesperetin interact with the DCF binding site, molecular docking simulations demonstrate that the two flavonoids act as orthosteric, not allosteric competitors of DCF, i.e., they block access of the substrate to the catalytic site through steric hindrance. The possibility of allosteric inhibition could not be excluded a priori, since some xenobiotics have been shown to bind to an allosteric site of CYP2C9 (see Si et al. 21) and references therein). Further investigations are being carried out in our laboratory to identify a possible ancillary binding site for hesperetin.
4) Diosmetin and hesperetin inhibit CYP2C9 activity by acting as dead-end inhibitors, not as alternative substrates, i.e., they``yield an enzyme-inhibitor complex that cannot participate in the reaction''. 26) Several in vitro studies have demonstrated oxidation or demethylation of various flavonoids by microsomal preparations obtained from different species (see Cermak and Wolffram 13) and references therein). In particular, demethylation has been reported for some molecules in which the methoxy group is at the 4?-position of the B ring, 13) as in the case of diosmetin and hesperetin. Although literature data indicate that demethylation of diosmetin and hesperetin is almost exclusively catalyzed by CYP1A enzymes, [45] [46] [47] we tested the possibility that these flavonoids also behave as substrates of CYP2C9, since interpretation of inhibition patterns differs according to whether inhibition is produced by a dead-end inhibitor or an alternative substrate. 26) Our results clearly demonstrate that neither diosmetin nor hesperetin is metabolized by rCYP2C9 in the presence of NADPH. This warrants that the interpretation of our kinetic results, based on the theory describing dead-end inhibition, 26) is correct. As mentioned above, diosmetin and hesperetin are present in various foods 8, 9) and medicinal products. The low Ki value (º2 mM) of diosmetin makes its pharmacokinetic interaction with drugs metabolized by CYP2C9 highly likely in vivo, since the high daily dosages at which its parent drug (the glycoside diosmin) is prescribed and the long in vivo elimination half-life of diosmetin (from 26 to 43 h 17, 19) ) are expected to cause a marked accumulation of this flavonoid. Inhibition of CYP2C9 activity is of considerable clinical relevance, since some CYP2C9 substrates are therapeutically important drugs with narrow therapeutic indexes. 39) Because of the very large interindividual variability of its effects, due both to genetic and environmental factors, warfarin is probably the most difficult to dose of these drugs. 48) Should a significant pharmacokinetic interaction between diosmetin and warfarin be confirmed in vivo, it would provide additional information regarding the still largely unexplained environmental variability (accounting for more than 50% of total variability) of the response to warfarin. 49) The present observations, together with the previously observed inhibition of CYP3A4/5 enzymes by diosmetin, 36) can also provide an explanation for the increase in bioavailability and the decrease in oral clearance of metronidazole (an anti-protozoal drug metabolized by CYP3A4 and CYP2C9 15) ) observed in healthy volunteers following diosmin co-administration. 15) In principle, as CYP2C9 is also expressed in human intestine, 50, 51) the in vivo effect of diosmin on the pharmacokinetics of co-administered drugs may be due to its inhibitory effect on intestinal CYP2C9 activity. However, it has been shown that orally administered diosmin and hesperidin, which are diglycosides, are not absorbed through the mucosa of the small intestine, the main site of intestinal drug metabolism, but are hydrolyzed to their respective aglycones diosmetin and hesperetin only by rhamnosidases produced by enterobacteria as they enter the cecum and colon, the sites of their absorption. 20) It is also well documented that CYP2C proteins and associated catalytic activities, although present in the more distal region of the small intestine, 52) are absent in the colon. 53) These considerations indicate that pharmacokinetic interactions between both diosmetin and hesperetin and co-administered drugs metabolized by CYP2C9 can only take place in the liver. Therefore, this fact strongly supports the use of HLMs for in vitro studies of these interactions.
